In 2002, the FDA approved Neulasta (pegfilgrastim), a PEGylated granulocyte colony-stimulating factor (PEG-G-CSF) injection developed by Amgen, which is used to treat a deficiency of white blood cells caused by cancer chemotherapy and some other cancers [10]. The gene discussed is CSF3; the disease is cancer.